HCP Live
Contagion LiveCGT LiveNeurology LiveHCP LiveOncology LiveContemporary PediatricsContemporary OBGYNEndocrinology NetworkPractical CardiologyRheumatology Netowrk



American College of Rheumatology Revises Guidelines for Treatment of Juvenile Idiopathic Arthritis

March 04, 2022

The American College of Rheumatology (ACR) has published guidance regarding the management of juvenile idiopathic arthritis, with emphasis placed on the treatment of systemic JIA and oligoarthritis, as well as non-pharmacologic therapies.

Guidelines for the Management of Pediatric Rheumatic Disease During the COVID-19 Pandemic

June 23, 2021

The American College of Rheumatology has updated its treatment guidelines for the management of pediatric rheumatic disease during the COVID-19 pandemic. The guideline includes 33 final guidance recommendations, 8 of which received moderate-to-high task force consensus.

Genomic Risk Scores May Enhance JIA Diagnosis

October 05, 2020

In juvenile idiopathic arthritis, predictive genomic risk scores may enhance current diagnosis protocols, prioritizing higher-risk patients for follow-up and reducing treatment delays, according to a study published this month in Annals of Rheumatic Diseases.

FDA Approves First-Ever Treatment for Pediatric GPA, MPA

December 20, 2019

The U.S. Food and Drug Administration has approved rituximab (Rituxan, Genentech) for the treatment of granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) in children 2 years of age and older in combination with glucocorticoids, to fulfil an unmet medical need for these rare and serious diseases in children.